Anavex Life Sciences Corp. (NASDAQ:AVXL) shares saw unusually-high trading volume on Thursday . Approximately 1,080,968 shares were traded during mid-day trading, an increase of 261% from the previous session’s volume of 299,122 shares.The stock last traded at $4.35 and had previously closed at $4.02.

AVXL has been the subject of several recent research reports. Zacks Investment Research raised Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Monday, August 28th. Maxim Group set a $15.00 price target on Anavex Life Sciences Corp. and gave the company a “buy” rating in a report on Monday, August 7th. Finally, ValuEngine cut Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research note on Friday, June 30th.

The firm’s market capitalization is $183.45 million. The stock has a 50 day moving average of $4.27 and a 200-day moving average of $4.27.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). Equities analysts expect that Anavex Life Sciences Corp. will post ($0.37) EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of AVXL. JPMorgan Chase & Co. acquired a new position in Anavex Life Sciences Corp. in the 1st quarter valued at $105,000. Northwest Investment Counselors LLC acquired a new position in Anavex Life Sciences Corp. in the 2nd quarter valued at $106,000. American International Group Inc. raised its holdings in Anavex Life Sciences Corp. by 7.1% in the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,329 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in Anavex Life Sciences Corp. in the 2nd quarter valued at $151,000. Finally, Alliancebernstein L.P. acquired a new position in Anavex Life Sciences Corp. in the 2nd quarter valued at $158,000. Institutional investors own 24.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Anavex Life Sciences Corp. (AVXL) Sees Strong Trading Volume” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/10/12/anavex-life-sciences-corp-avxl-sees-strong-trading-volume.html.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.